Allogene Therapeutics, Inc.

NASDAQ:ALLO

2.72 (USD) • At close November 13, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42018 Q32018 Q22018 Q12017 Q4
Revenue 000.0220.0210.0430.0440.0520.0470.0490.0860.0610.0510.0490.04438.3450000000000000
Cost of Revenue 03.6443.55554.6613.5723.7933.7143.30863.6414.84960.1564.24258.722.3513.92552.22851.42147.2960000000000
Gross Profit 0-3.644-3.533-54.64-3.529-3.749-3.662-3.261-63.592-4.763-60.095-4.191-58.671-2.30734.42-52.228-51.421-47.2960000000000
Gross Profit Ratio 00-160.591-2,601.905-82.07-85.205-70.423-69.383-1,297.796-55.384-985.164-82.176-1,197.367-52.4320.8980000000000000
Reseach & Development Expenses 44.71346.71148.70454.66145.97762.03880.23875.41963.64157.17160.15653.98358.7252.2955.18352.22851.42147.29642.04249.36339.99531.77423.40318.50310.87122.48600
General & Administrative Expenses 16.33316.08717.26717.22417.04118.52418.88421.00218.89719.50919.89719.96118.99918.78316.36317.13416.61915.86215.64115.21215.01614.18713.05814.54311.31712.5262.5970
Selling & Marketing Expenses 0000000000000000000000000000
SG&A 16.33316.08717.26717.22417.04118.52418.88421.00218.89719.50919.89719.96118.99918.78316.36317.13416.61915.86215.64115.21215.01614.18713.05814.54311.31712.5262.5970.002
Other Expenses 10.7280.085-0.929-10.348-4.545-1.249-1.693-1.23-1.6611.492-0.35-1.161-0.909-0.531-0.325-0.766-0.162-0.156-0.058-0.268000-1.796-19.415000
Operating Expenses 71.77462.79865.97171.88563.01880.56299.12296.42182.53876.6880.05373.94477.71971.07371.54669.36268.0463.15857.68364.57555.01145.96136.46133.04622.187135.0122.5970.002
Operating Income -71.774-66.442-69.504-71.864-62.975-80.518-99.07-96.374-82.489-76.594-79.992-73.893-77.67-71.029-33.201-69.362-68.04-63.158-57.683-64.575-55.011-45.961-36.461-33.046-22.187-135.012-2.597-0.002
Operating Income Ratio 00-3,159.273-3,422.095-1,464.535-1,829.955-1,905.192-2,050.511-1,683.449-890.628-1,311.344-1,448.882-1,585.102-1,614.295-0.8660000000000000
Total Other Income Expenses Net 5.4815.0734.504-4.0831.662.5290.3661.527-0.6591.8070.142-0.975-0.5160.0930.1860.7921.8432.1843.2033.394.3094.5594.8252.42-21.310.1100
Income Before Tax -66.293-66.358-65-85.778-61.315-77.989-98.704-94.847-83.148-74.787-79.85-74.868-78.186-70.936-33.015-68.57-66.197-60.974-54.48-61.185-50.702-41.402-31.636-30.626-43.497-134.902-2.597-0.002
Income Before Tax Ratio 00-2,954.545-4,084.667-1,425.93-1,772.477-1,898.154-2,018.021-1,696.898-869.616-1,309.016-1,468-1,595.633-1,612.182-0.8610000000000000
Income Tax Expense 0-03.512-0.065-6.205-3.778-0.366-1.527-1.002-0.315-0.142-4.428-0.393-0.624-0.511-3.402-3.815-2.34-3.261-0.1550.033-0.159-0.05-0.117-16.0570-2.5970
Net Income -66.293-66.358-65-85.778-61.315-77.989-98.338-93.32-83.148-74.472-79.708-74.868-78.186-70.936-33.015-68.57-66.197-60.974-54.48-61.03-50.735-41.243-31.586-30.509-43.497-134.902-2.597-0.002
Net Income Ratio 00-2,954.545-4,084.667-1,425.93-1,772.477-1,891.115-1,985.532-1,696.898-865.953-1,306.689-1,468-1,595.633-1,612.182-0.8610000000000000
EPS -0.32-0.35-0.38-0.51-0.37-0.53-0.68-0.65-0.58-0.52-0.56-0.54-0.57-0.53-0.25-0.53-0.52-0.53-0.5-0.58-0.5-0.41-0.32-0.37-0.38-1.19-0.0590
EPS Diluted -0.32-0.35-0.38-0.51-0.37-0.53-0.68-0.65-0.58-0.52-0.56-0.54-0.57-0.53-0.25-0.53-0.52-0.53-0.5-0.58-0.5-0.41-0.32-0.37-0.38-1.19-0.0590
EBITDA -71.774-62.798-65.949-68.452-59.403-76.897-95.585-93.306-78.629-72.919-76.3-69.651-75.34-69.065-31.283-64.011-66.23-61.27-55.639-59.33-53.683-44.812-35.766-30.079-39.636-134.562-2.597-0.002
EBITDA Ratio 00-2,997.682-3,259.619-1,381.465-1,747.159-1,905.192-2,050.511-1,604.673-847.895-1,250.82-1,448.882-1,537.551-1,569.659-0.8160000000000000